We also found that bortezomib treatment increased priming and dependencies on pro-survival proteins BCL-2 and MCL-1, suggesting that the results we observed in clonal plasma cells are likely due to a conserved signaling pathway in this cell lineage and exploited therapeutically for AL therapy (Fig. 7h). Here, BCL2 is linked to axial length measurement.